Related Experiment Videos

Epidemiology and optimal management of polymyalgia rheumatica

P Labbe1, P Hardouin

  • 1Department of Rheumatology, Centre Hospitalier Spécialisé, Institut Calot, Berck sur Mer, France.

Drugs & Aging
|September 18, 1998
PubMed

Insights

Polymyalgia rheumatica (PMR) is an inflammatory condition primarily affecting older adults. Oral corticosteroids are the primary treatment, offering rapid symptom relief, though optimal dosing and duration remain debated.

Area of Science:

  • Rheumatology
  • Internal Medicine
  • Geriatrics

Background:

  • Polymyalgia rheumatica (PMR) is a disease of unknown cause affecting elderly Caucasians, with higher prevalence in women.
  • PMR is increasingly recognized as closely related to giant cell arteritis and has associations with rheumatoid arthritis, myopathy, and malignancy.

Purpose of the Study:

  • To summarize current understanding of polymyalgia rheumatica (PMR) etiology, associations, and management.
  • To highlight the diagnostic role of corticosteroid response and discuss treatment controversies.

Main Methods:

  • Literature review and synthesis of existing studies on PMR.
  • Analysis of the relationship between PMR, giant cell arteritis, and other conditions.
  • Evaluation of current therapeutic strategies for PMR.

Main Results:

  • Oral corticosteroids are the primary therapy, providing prompt symptom relief, often considered diagnostic.
  • Debate exists regarding optimal corticosteroid dosage, treatment duration, and tapering schedules.
  • Corticosteroid-sparing agents like methotrexate and azathioprine are considered, while NSAIDs are generally unsuitable for long-term PMR treatment.

Conclusions:

  • PMR management primarily relies on oral corticosteroids, with ongoing research into optimal treatment protocols.
  • Understanding PMR's associations is crucial for comprehensive patient care.
  • Further research is needed to explore alternative and steroid-sparing therapies.

Related Concept Videos